Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Welcome and Introduction to Vi3C

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Sep
02
Today In Oncology
Radiation to the Thymus in NSCLC Treatment May Increase Risk of Metastasis
Osimertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in EGFR/TP53-Mutated NSCLC
Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo